Rheims, 2013, Profile of perampanel and its potential in the treatment of partial onset seizures, Neuropsychiatr Dis Treat, 9, 629, 10.2147/NDT.S30129
Kwan, 2011, Drug-resistant epilepsy, N Engl J Med, 365, 919, 10.1056/NEJMra1004418
Stephen, 2012, Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults, Curr Opin Neurol, 25, 164, 10.1097/WCO.0b013e328350ba68
Faught, 2012, Antiepileptic drug trials: the view from the clinic, Epileptic Disord, 14, 114, 10.1684/epd.2012.0510
Marson, 2009, Interpreting regulatory trials in epilepsy, Curr Opin Neurol, 22, 167, 10.1097/WCO.0b013e3283292427
Brodie, 2013, Meta-analyses of antiepileptic drugs for refractory partial (focal) epilepsy: an observation, Br J Clin Pharmacol, 76, 630, 10.1111/bcp.12176
Brodie, 2014, Prospective audits with newer antiepileptic drugs in focal epilepsy: insights into population responses?, Epilepsy Behav, 31, 73, 10.1016/j.yebeh.2013.11.016
Wedzony, 2008, Impact of postnatal blockade of N-methyl-d-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia, Neuroscience, 153, 1370, 10.1016/j.neuroscience.2008.03.016
Nabeshima, 2006, Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine, Ann N Y Acad Sci, 1086, 160, 10.1196/annals.1377.003
French, 2012, Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304, Neurology, 79, 589, 10.1212/WNL.0b013e3182635735
Krauss, 2012, Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures, Neurology, 78, 1408, 10.1212/WNL.0b013e318254473a
Steinhoff, 2013, Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies, Epilepsia, 54, 1481, 10.1111/epi.12212
Chen, 2014, Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons, PLOS ONE, 9, e108021, 10.1371/journal.pone.0108021
Hanada, 2011, Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy, Epilepsia, 52, 1331, 10.1111/j.1528-1167.2011.03109.x
Krauss, 2013, Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase 3, extension study 307, Epilepsia, 54, 126, 10.1111/j.1528-1167.2012.03648.x
Krauss, 2014, Longterm safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307, Epilepsia, 55, 1058, 10.1111/epi.12643
Khan, 2013, The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis, Curr Med Res Opin, 29, 1001, 10.1185/03007995.2013.803461
Ettinger, 2015, Psychiatric and behavioural adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel, Epilepsia, 56, 1252, 10.1111/epi.13054
Steinhoff, 2014, Safety profile of perampanel as an adjunctive treatment for partial onset seizures, J Symptoms Signs, 3, 64
Sirven, 2007, Second-generation antiepileptic drugs’ impact on balance: a meta-analysis, Mayo Clin Proc, 82, 40, 10.1016/S0025-6196(11)60965-8
